{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T12:11:46Z","timestamp":1776255106988,"version":"3.50.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"vor","delay-in-days":37,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"VitreoRetinal Surgery Foundation Research Award"},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"crossref","award":["1R01EY034325, 1R01EY033000"],"award-info":[{"award-number":["1R01EY034325, 1R01EY033000"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Alcon Research Institute Young Investigator Grant"},{"name":"University of Michigan MTRAC-FFMI Kickstart"},{"name":"Fight for Sight- International Retinal Research Foundation","award":["FFSGIA16002"],"award-info":[{"award-number":["FFSGIA16002"]}]},{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Diabetic Retinopathy (DR), a leading cause of preventable blindness, is conventionally evaluated using seven-field retinal fundus photography. Ultra-widefield fluorescein angiography (UWF FA) allows for detailed visualization and quantification of peripheral retinal non-perfusion (NP). This study aims to assess changes in NP and neovascularization (NV) following intravitreal anti-VEGF and steroid treatments using UWF FA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective, single-center cohort study included 65 eyes from 45 patients with Type 1 or 2 diabetes mellitus (DM) and UWF FA images acquired across two visits. Images were manually segmented by masked, trained graders, annotating foveal avascular zone (FAZ), NP, and NV surface areas. Patient demographics, clinical history, and treatment details were extracted via chart review. Stepwise multivariate linear regression identified predictors of changes in FAZ, NP, and NV areas, while causal modeling estimated effects of anti-VEGF and steroid treatments over time.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Eyes treated with steroid injections (\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u200913) had decreased total and mid-periphery retinal NP areas compared to untreated eyes or eyes that received anti-VEGF alone (total change in NP area: 4.32\u2009\u00b1\u200924.66 vs. 32.30\u2009\u00b1\u200965.40 vs. 27.21\u2009\u00b1\u200942.09 mm\n                      <jats:sup>2<\/jats:sup>\n                      ;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05). Increased frequency of steroid injections predicted decreased FAZ area (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0036). Longer duration between FAs was associated with larger NP areas by 0.87 mm\n                      <jats:sup>2<\/jats:sup>\n                      per additional month (95% CI, 0.25 to 1.5;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0072), whereas more steroid injections (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.035), DME on initial clinical presentation (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.013), and vitreous hemorrhage development (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0002) were associated with decreased NP areas. Compared to eyes in type 1 diabetics, eyes with type 2 DM were associated with \u2212\u200956.45 mm\n                      <jats:sup>2<\/jats:sup>\n                      smaller total NP areas over time (95% CI, -92.3 to -20.52;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0028). Causal analyses suggest each additional steroid injection was associated with a 31.38 mm\n                      <jats:sup>2<\/jats:sup>\n                      decrease in total NP area (95% CI, -58.14 to -4.62;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.022). Anti-VEGF treatment (\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u200928) did not have a significant effect on FAZ (95% CI, -0.153 to 0.060;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.40), NP (95% CI, -17.20 to 3.91;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.22), or NV areas (95% CI, -0.391 to 0.282;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.75).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Compared to anti-VEGF, intravitreal steroids produced significant improvement in retinal perfusion. Quantitative biomarkers from UWF FA may provide an objective approach to assessing treatment response and DR severity over time.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>Not applicable.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12886-026-04708-w","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T08:23:21Z","timestamp":1773044601000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Quantifying changes in retinal non-perfusion over time with ultra-widefield fluorescein angiography following intravitreal treatment of diabetic retinopathy"],"prefix":"10.1186","volume":"26","author":[{"given":"Callie","family":"Deng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karthik","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikhil","family":"Bommakanti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Rosenthal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yannis M.","family":"Paulus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,9]]},"reference":[{"issue":"11","key":"4708_CR1","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1038\/s41433-024-03101-5","volume":"38","author":"Vision Loss Expert Group of the Global Burden of Disease Study; GBD 2019 Blindness and Vision Impairment Collaborators","year":"2024","unstructured":"Vision Loss Expert Group of the Global Burden of Disease Study; GBD 2019 Blindness and Vision Impairment Collaborators. Global estimates on the number of people blind or visually impaired by diabetic retinopathy: a meta-analysis from 2000 to 2020. Eye (Lond). 2024;38(11):2047\u201357. https:\/\/doi.org\/10.1038\/s41433-024-03101-5.","journal-title":"Eye (Lond)"},{"issue":"8","key":"4708_CR2","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1001\/jamaophthalmol.2023.2289","volume":"141","author":"EA Lundeen","year":"2023","unstructured":"Lundeen EA, Burke-Conte Z, Rein DB, et al. Prevalence of Diabetic Retinopathy in the US in 2021. JAMA Ophthalmol. 2023;141(8):747\u201354. https:\/\/doi.org\/10.1001\/jamaophthalmol.2023.2289.","journal-title":"JAMA Ophthalmol"},{"issue":"12","key":"4708_CR3","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.4103\/ijo.IJO_1217_18","volume":"66","author":"MW Stewart","year":"2018","unstructured":"Stewart MW, Browning DJ, Landers MB. Current management of diabetic tractional retinal detachments. Indian J Ophthalmol. 2018;66(12):1751\u201362. https:\/\/doi.org\/10.4103\/ijo.IJO_1217_18.","journal-title":"Indian J Ophthalmol"},{"issue":"5","key":"4708_CR4","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/S0161-6420(13)38012-9","volume":"98","author":"Early Treatment Diabetic Retinopathy Study Research Group","year":"1991","unstructured":"Early Treatment Diabetic Retinopathy Study Research Group. Grading diabetic retinopathy from stereoscopic color fundus photographs: an extension of the modified Airlie House classification. ETDRS report number 10. Ophthalmology. 1991;98(5):786\u2013806. https:\/\/doi.org\/10.1016\/S0161-6420(13)38012-9.","journal-title":"Ophthalmology"},{"issue":"15","key":"4708_CR5","doi-asserted-by":"publisher","first-page":"3300","DOI":"10.3390\/jcm10153300","volume":"10","author":"M Ashraf","year":"2021","unstructured":"Ashraf M, Cavallerano JD, Sun JK, Silva PS, Aiello LP. Ultrawide Field Imaging in Diabetic Retinopathy: Exploring the Role of Quantitative Metrics. J Clin Med. 2021;10(15):3300. https:\/\/doi.org\/10.3390\/jcm10153300.","journal-title":"J Clin Med"},{"key":"4708_CR6","doi-asserted-by":"publisher","unstructured":"Patel SN, Shi A, Wibbelsman TD, Klufas MA. Ultra-widefield retinal imaging: an update on recent advances. Ther Adv Ophthalmol. 2020;12. https:\/\/doi.org\/10.1177\/2515841419899495.","DOI":"10.1177\/2515841419899495"},{"key":"4708_CR7","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.visres.2017.02.009","volume":"139","author":"K Ghasemi Falavarjani","year":"2017","unstructured":"Ghasemi Falavarjani K, Tsui I, Sadda SR. Ultra-wide-field imaging in diabetic retinopathy. Vis Res. 2017;139:187\u201390. https:\/\/doi.org\/10.1016\/j.visres.2017.02.009.","journal-title":"Vis Res"},{"key":"4708_CR8","doi-asserted-by":"publisher","first-page":"2946","DOI":"10.1038\/s41433-023-02445-8","volume":"37","author":"Y Attiku","year":"2023","unstructured":"Attiku Y, Nittala MG, Velaga SB, et al. Comparison of diabetic retinopathy severity grading on ETDRS 7-field versus ultra-widefield assessment. Eye. 2023;37:2946\u20139. https:\/\/doi.org\/10.1038\/s41433-023-02445-8.","journal-title":"Eye"},{"issue":"12","key":"4708_CR9","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1016\/j.ophtha.2013.05.004","volume":"120","author":"PS Silva","year":"2013","unstructured":"Silva PS, Cavallerano JD, Sun JK, Soliman AZ, Aiello LM, Aiello LP. Peripheral lesions identified by mydriatic ultrawide field imaging: distribution and potential impact on diabetic retinopathy severity. Ophthalmology. 2013;120(12):2587\u201395. https:\/\/doi.org\/10.1016\/j.ophtha.2013.05.004.","journal-title":"Ophthalmology"},{"issue":"4","key":"4708_CR10","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1097\/IAE.0b013e3182278b64","volume":"32","author":"MM Wessel","year":"2012","unstructured":"Wessel MM, Aaker GD, Parlitsis G, Cho M, D\u2019Amico DJ, Kiss S, Ultra\u2013wide-field, angiography improves the detection and classification of diabetic retinopathy. Retina. 2012;32(4):785\u201391. https:\/\/doi.org\/10.1097\/IAE.0b013e3182278b64.","journal-title":"Retina"},{"issue":"5","key":"4708_CR11","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/j.ophtha.2015","volume":"122","author":"PS Silva","year":"2015","unstructured":"Silva PS, Cavallerano JD, Haddad NM, et al. Peripheral lesions identified on ultrawide field imaging predict increased risk of diabetic retinopathy progression over 4 years. Ophthalmology. 2015;122(5):949\u201356. https:\/\/doi.org\/10.1016\/j.ophtha.2015. 01.008.","journal-title":"Ophthalmology"},{"issue":"14","key":"4708_CR12","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1080\/14656566.2023.2230139","volume":"24","author":"SM Muns","year":"2023","unstructured":"Muns SM, Villegas VM, Flynn HW Jr, Schwartz SG. Update on current pharmacologic therapies for diabetic retinopathy. Expert Opin Pharmacother. 2023;24(14):1577\u201393. https:\/\/doi.org\/10.1080\/14656566.2023.2230139.","journal-title":"Expert Opin Pharmacother"},{"issue":"6","key":"4708_CR13","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1097\/ICU.0000000000000424","volume":"28","author":"S Cai","year":"2017","unstructured":"Cai S, Bressler NM. Aflibercept, bevacizumab or ranibizumab for diabetic macular oedema: recent clinically relevant findings from DRCR.net Protocol T. Curr Opin Ophthalmol. 2017;28(6):636\u201343. https:\/\/doi.org\/10.1097\/ICU.0000000000000424.","journal-title":"Curr Opin Ophthalmol"},{"issue":"10","key":"4708_CR14","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1080\/14712598.2023.2247987","volume":"23","author":"A Shughoury","year":"2023","unstructured":"Shughoury A, Bhatwadekar A, Jusufbegovic D, Hajrasouliha A, Ciulla TA. The evolving therapeutic landscape of diabetic retinopathy. Expert Opin Biol Ther. 2023;23(10):969\u201385. https:\/\/doi.org\/10.1080\/14712598.2023.2247987.","journal-title":"Expert Opin Biol Ther"},{"issue":"10","key":"4708_CR15","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1080\/14712598.2022.2100694","volume":"22","author":"G Uludag","year":"2022","unstructured":"Uludag G, Hassan M, Matsumiya W, Pham BH, Chea S, Trong Tuong Than N, et al. Efficacy and safety of intravitreal anti-VEGF therapy in diabetic retinopathy: what we have learned and what should we learn further? Expert Opin Biol Ther. 2022;22(10):1275\u201391. https:\/\/doi.org\/10.1080\/14712598.2022.2100694.","journal-title":"Expert Opin Biol Ther"},{"issue":"13","key":"4708_CR16","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1056\/NEJMoa1414264","volume":"372","author":"JA Wells","year":"2015","unstructured":"Diabetic Retinopathy Clinical Research Network, Wells JA, Glassman AR, Ayala AR, Jampol LM, Aiello LP, Antoszyk AN, Arnold-Bush B, Baker CW, Bressler NM, Browning DJ, Elman MJ, Ferris FL, Friedman SM, Melia M, Pieramici DJ, Sun JK, Beck RW. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015;372(13):1193\u2013203. https:\/\/doi.org\/10.1056\/NEJMoa1414264.","journal-title":"N Engl J Med"},{"issue":"4","key":"4708_CR17","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.ophtha.2011.12.039","volume":"119","author":"QD Nguyen","year":"2012","unstructured":"Nguyen QD, Brown DM, Marcus DM, Boyer DS, Patel S, Feiner L, Gibson A, Sy J, Rundle AC, Hopkins JJ, Rubio RG, Ehrlich JS, RISE and RIDE Research Group. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119(4):789\u2013801. https:\/\/doi.org\/10.1016\/j.ophtha.2011.12.039.","journal-title":"Ophthalmology"},{"key":"4708_CR18","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/sj.eye.6702980","volume":"23","author":"J Arevalo","year":"2009","unstructured":"Arevalo J, Wu L, Sanchez J, et al. Intravitreal bevacizumab (Avastin) for proliferative diabetic retinopathy: 6-month follow-up. Eye. 2009;23:117\u201323. https:\/\/doi.org\/10.1038\/sj.eye.6702980.","journal-title":"Eye"},{"issue":"1","key":"4708_CR19","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.ophtha.2018.08.001","volume":"126","author":"JK Sun","year":"2019","unstructured":"Sun JK, Glassman AR, Beaulieu WT, Stockdale CR, Bressler NM, Flaxel C, Gross JG, Shami M, Jampol LM, Diabetic Retinopathy Clinical Research Network. Rationale and Application of the Protocol S Anti-Vascular Endothelial Growth Factor Algorithm for Proliferative Diabetic Retinopathy. Ophthalmology. 2019;126(1):87\u201395. https:\/\/doi.org\/10.1016\/j.ophtha.2018.08.001.","journal-title":"Ophthalmology"},{"issue":"5","key":"4708_CR20","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1001\/jamaophthalmol.2021.0108","volume":"139","author":"S Halim","year":"2021","unstructured":"Halim S, Nugawela M, Chakravarthy U, Peto T, Madhusudhan S, Lenfestey P, Hamill B, Zheng Y, Parry D, Nicholson L, Greenwood J, Sivaprasad S. Topographical Response of Retinal Neovascularization to Aflibercept or Panretinal Photocoagulation in Proliferative Diabetic Retinopathy: Post Hoc Analysis of the CLARITY Randomized Clinical Trial. JAMA Ophthalmol. 2021;139(5):501\u20137. https:\/\/doi.org\/10.1001\/jamaophthalmol.2021.0108.","journal-title":"JAMA Ophthalmol"},{"key":"4708_CR21","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1111\/j.1600-0420.2007.01056.x","volume":"86","author":"M Tonello","year":"2008","unstructured":"Tonello M, Costa RA, Almeida FPP, Barbosa JC, Scott IU, Jorge R. Panretinal photocoagulation versus PRP plus intravitreal bevacizumab for high-risk proliferative diabetic retinopathy (IBeHi study). Acta Ophthalmol. 2008;86:385\u20139. https:\/\/doi.org\/10.1111\/j.1600-0420.2007.01056.x.","journal-title":"Acta Ophthalmol"},{"issue":"6","key":"4708_CR22","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1001\/jamaophthalmol.2017.0821","volume":"135","author":"SB Bressler","year":"2017","unstructured":"Bressler SB, Liu D, Glassman AR, Blodi BA, Castellarin AA, Jampol LM, Kaufman PL, Melia M, Singh H, Wells JA. Diabetic Retinopathy Clinical Research Network. Change in Diabetic Retinopathy Through 2 Years: Secondary Analysis of a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and Ranibizumab. JAMA Ophthalmol. 2017;135(6):558\u201368. https:\/\/doi.org\/10.1001\/jamaophthalmol.2017.0821.","journal-title":"JAMA Ophthalmol"},{"issue":"9","key":"4708_CR23","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1001\/jamaophthalmol.2021.2809","volume":"139","author":"DM Brown","year":"2021","unstructured":"Brown DM, Wykoff CC, Boyer D, et al. Evaluation of Intravitreal Aflibercept for the Treatment of Severe Nonproliferative Diabetic Retinopathy: Results From the PANORAMA Randomized Clinical Trial. JAMA Ophthalmol. 2021;139(9):946\u201355. https:\/\/doi.org\/10.1001\/jamaophthalmol.2021.2809.","journal-title":"JAMA Ophthalmol"},{"issue":"12","key":"4708_CR24","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.4103\/ijo.IJO_1240_18","volume":"66","author":"DJ Browning","year":"2018","unstructured":"Browning DJ, Stewart MW, Lee C. Diabetic macular edema: Evidence-based management. Indian J Ophthalmol. 2018;66(12):1736\u201350. https:\/\/doi.org\/10.4103\/ijo.IJO_1240_18.","journal-title":"Indian J Ophthalmol"},{"issue":"8","key":"4708_CR25","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1248\/bpb.31.1541","volume":"31","author":"K Wang","year":"2008","unstructured":"Wang K, Wang Y, Gao L, Li X, Li M, Guo J. Dexamethasone inhibits leukocyte accumulation and vascular permeability in retina of streptozotocin-induced diabetic rats via reducing vascular endothelial growth factor and intercellular adhesion molecule-1 expression. Biol Pharm Bull. 2008;31(8):1541\u20136. https:\/\/doi.org\/10.1248\/bpb.31.1541.","journal-title":"Biol Pharm Bull"},{"issue":"6","key":"4708_CR26","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s00592-018-1117-z","volume":"55","author":"M Iglicki","year":"2018","unstructured":"Iglicki M, Zur D, Busch C, Okada M, Loewenstein A. Progression of diabetic retinopathy severity after treatment with dexamethasone implant: a 24-month cohort study the \u2018DR-Pro-DEX Study\u2019. Acta Diabetol. 2018;55(6):541\u20137. https:\/\/doi.org\/10.1007\/s00592-018-1117-z.","journal-title":"Acta Diabetol"},{"issue":"4","key":"4708_CR27","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.3390\/jcm12041365","volume":"12","author":"JB Morel","year":"2023","unstructured":"Morel JB, Fajnkuchen F, Amari F, Sritharan N, Bloch-Queyrat C, Giocanti-Aur\u00e9gan A. Ultra-Wide-Field Fluorescein Angiography Assessment of Non-Perfusion in Patients with Diabetic Retinopathy Treated with Anti-Vascular Endothelial Growth Factor Therapy. J Clin Med. 2023;12(4):1365. https:\/\/doi.org\/10.3390\/jcm12041365.","journal-title":"J Clin Med"},{"issue":"12","key":"4708_CR28","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1016\/j.ophtha.2019.06.022","volume":"126","author":"A Couturier","year":"2019","unstructured":"Couturier A, Rey PA, Erginay A, Lavia C, Bonnin S, Dupas B, Gaudric A, Tadayoni R. Widefield OCT-Angiography and Fluorescein Angiography Assessments of Non-perfusion in Diabetic Retinopathy and Edema Treated with Anti-Vascular Endothelial Growth Factor. Ophthalmology. 2019;126(12):1685\u201394. https:\/\/doi.org\/10.1016\/j.ophtha.2019.06.022.","journal-title":"Ophthalmology"},{"issue":"5","key":"4708_CR29","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s00592-019-01435-1","volume":"57","author":"E Borrelli","year":"2020","unstructured":"Borrelli E, Parravano M, Querques L, Sacconi R, Giorno P, De Geronimo D, et al. One-year follow-up of ischemic index changes after intravitreal dexamethasone implant for diabetic macular edema: an ultra-widefield fluorescein angiography study. Acta Diabetol. 2020;57(5):543\u20138. https:\/\/doi.org\/10.1007\/s00592-019-01435-1.","journal-title":"Acta Diabetol"},{"issue":"4","key":"4708_CR30","doi-asserted-by":"publisher","first-page":"312","DOI":"10.3928\/23258160-20140709-07","volume":"45","author":"DE Croft","year":"2014","unstructured":"Croft DE, van Hemert J, Wykoff CC, Clifton D, Verhoek M, Fleming A, Brown DM. Precise montaging and metric quantification of retinal surface area from ultra-widefield fundus photography and fluorescein angiography. Ophthalmic Surg Lasers Imaging Retina. 2014;45(4):312\u20137. https:\/\/doi.org\/10.3928\/23258160-20140709-07.","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"issue":"3","key":"4708_CR31","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1016\/j.neuroimage.2006.01.015","volume":"31","author":"PA Yushkevich","year":"2006","unstructured":"Yushkevich PA, Piven J, Hazlett HC, et al. User-guided 3D active contour segmentation of anatomical structures: significantly improved efficiency and reliability. NeuroImage. 2006;31(3):1116\u201328. https:\/\/doi.org\/10.1016\/j.neuroimage.2006.01.015.","journal-title":"NeuroImage"},{"issue":"6","key":"4708_CR32","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1001\/jamaophthalmol.2020.1257","volume":"138","author":"G Yu","year":"2020","unstructured":"Yu G, Aaberg MT, Patel TP, et al. Quantification of Retinal Nonperfusion and Neovascularization With Ultrawidefield Fluorescein Angiography in Patients With Diabetes and Associated Characteristics of Advanced Disease. JAMA Ophthalmol. 2020;138(6):680\u20138. https:\/\/doi.org\/10.1001\/jamaophthalmol.2020.1257.","journal-title":"JAMA Ophthalmol"},{"key":"4708_CR33","unstructured":"R. the R project for statistical computing. Available from: https:\/\/www.r-project.org\/. Accessed September 10, 2024."},{"key":"4708_CR34","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.2147\/OPTH.S462223","volume":"18","author":"S Fleifil","year":"2024","unstructured":"Fleifil S, Azzouz L, Yu G, Powell C, Bommakanti N, Paulus YM. Quantitative Biomarkers of Diabetic Retinopathy Using Ultra-Widefield Fluorescein Angiography. Clin Ophthalmol. 2024;18:1961\u201370. https:\/\/doi.org\/10.2147\/OPTH.S462223.","journal-title":"Clin Ophthalmol"},{"issue":"4","key":"4708_CR35","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.2337\/db07-0982","volume":"57","author":"X Zhang","year":"2008","unstructured":"Zhang X, Bao S, Lai D, Rapkins RW, Gillies MC. Intravitreal triamcinolone acetonide inhibits breakdown of the blood-retinal barrier through differential regulation of VEGF-A and its receptors in early diabetic rat retinas. Diabetes. 2008;57(4):1026\u201333. https:\/\/doi.org\/10.2337\/db07-0982.","journal-title":"Diabetes"},{"issue":"4","key":"4708_CR36","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1038\/s41433-021-01750-4a","volume":"36","author":"I Chatziralli","year":"2022","unstructured":"Chatziralli I, Touhami S, Cicinelli MV, et al. Disentangling the association between retinal non-perfusion and anti-VEGF agents in diabetic retinopathy. Eye (Lond). 2022;36(4):692\u2013703. https:\/\/doi.org\/10.1038\/s41433-021-01750-4a.","journal-title":"Eye (Lond)"},{"issue":"10","key":"4708_CR37","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1001\/jamaophthalmol.2022.3130","volume":"140","author":"PS Silva","year":"2022","unstructured":"Silva PS, Marcus DM, Liu D, et al. Association of Ultra-Widefield Fluorescein Angiography-Identified Retinal Nonperfusion and the Risk of Diabetic Retinopathy Worsening Over Time. JAMA Ophthalmol. 2022;140(10):936\u201345. https:\/\/doi.org\/10.1001\/jamaophthalmol.2022.3130.","journal-title":"JAMA Ophthalmol"},{"issue":"Supplement1","key":"4708_CR38","doi-asserted-by":"publisher","first-page":"501","DOI":"10.2337\/db23-501-P","volume":"72","author":"JM Breen","year":"2023","unstructured":"Breen JM, Cooper A, Stevens H, Cooper BA. 501-P: Differences in Disease Severity and Treatment for Diabetes-Related Retinopathy between Type 1 and 2 Diabetes Mellitus. Diabetes 20 June. 2023;72(Supplement1):501\u2013P. https:\/\/doi.org\/10.2337\/db23-501-P.","journal-title":"Diabetes 20 June"},{"issue":"10","key":"4708_CR39","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1136\/bjophthalmol-2016-310063","volume":"101","author":"P Romero-Aroca","year":"2017","unstructured":"Romero-Aroca P, Navarro-Gil R, Valls-Mateu A, Sagarra-Alamo R, Moreno-Ribas A, Soler N. Differences in incidence of diabetic retinopathy between type 1 and 2 diabetes mellitus: a nine-year follow-up study. Br J Ophthalmol. 2017;101(10):1346\u201351. https:\/\/doi.org\/10.1136\/bjophthalmol-2016-310063.","journal-title":"Br J Ophthalmol"},{"issue":"12","key":"4708_CR40","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1016\/j.ophtha.2015.07.034","volume":"122","author":"PS Silva","year":"2015","unstructured":"Silva PS, Dela Cruz AJ, Ledesma MG, van Hemert J, Radwan A, Cavallerano JD, Aiello LM, Sun JK, Aiello LP. Diabetic Retinopathy Severity and Peripheral Lesions Are Associated with Non-perfusion on Ultrawide Field Angiography. Ophthalmology. 2015;122(12):2465\u201372. https:\/\/doi.org\/10.1016\/j.ophtha.2015.07.034.","journal-title":"Ophthalmology"},{"key":"4708_CR41","doi-asserted-by":"crossref","unstructured":"Silva PS, Marcus DM, Liu D et al. Association of ultra-widefield fluorescein angiography-identified retinal non-perfusion and the risk of diabetic retinopathy worsening over time [published correction appears in JAMA Ophthalmol. 2023;141(1):104. https:\/\/doi.org\/10.1001\/jamaophthalmol.2022.5277]. JAMA Ophthalmol. 2022;140(10):936\u2013945. https:\/\/doi.org\/10.1001\/jamaophthalmol.2022.3130.","DOI":"10.1001\/jamaophthalmol.2022.3130"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12886-026-04708-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-026-04708-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-026-04708-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T11:26:38Z","timestamp":1776252398000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12886-026-04708-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,9]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4708"],"URL":"https:\/\/doi.org\/10.1186\/s12886-026-04708-w","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,9]]},"assertion":[{"value":"1 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the tenets of the Declaration of Helsinki. Ethics approval was obtained from the University of Michigan Institutional Review Board (HUM00120509, PI: Y. M. Paulus). A waiver of consent was obtained from the University of Michigan Institutional Review Board in accordance with the Health Insurance Portability and Accountability Act.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"183"}}